Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 2 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

542 A first-in-human phase 1/2 study of XTX501, a bispecific PD-1/masked IL-2, in metastatic non-small cell lung cancer (NSCLC)

  • Damiano Fantini1
  • Scott Coleman2
  • Ekta Patel3
  • Meghan Duncan4
  • Martin Huber1
  • Benjamin Nicholson5
  • David Crowe4
  • Scott McConnell3
  • Patricia Bernardo1
  • Myra W Popejoy1
  • Carl Uli Bialucha1
5 affiliations
  1. 1Xilio Therapeutics, Inc., Waltham, MA, USA
  2. 21Xilio Therapeutics, Waltham, MA, USA
  3. 314Xilio Therapeutics, Waltham, MA, USA
  4. 48Xilio Therapeutics, Waltham, MA, USA
  5. 5Xilio Therapeutics, Waltham, Massachusetts, USA
Open at sourcePDFDOICite

Related

  1. PF chemotherapy combined with a PD-1/CTLA-4 bispecific antibody as first-line treatment in patients with recurrent/metastatic head and neck squamous cell carcinoma: a prospective, single-arm, phase II clinical study
    Wenjun Liao, Qiaohua Li, Yue Deng +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  2. EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study
    Ting Xu, Christine M. Parseghian, Yanqiao Zhang +15
    Clinical Cancer ResearchPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  3. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref
  4. Nanoparticle polymeric micellar paclitaxel (pm-Pac), platinum, and sintilimab as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer: a phase II study
    Xiaohua Wang, Li Wang, Shaorong Yu +13
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  5. The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
    Anna Maria Di Giacomo, Matteo Simonelli, Agnese Losurdo +37
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full text3 citedGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{fantini2026firstinhuman,
  title = {{542 A first-in-human phase 1/2 study of XTX501, a bispecific PD-1/masked IL-2, in metastatic non-small cell lung cancer (NSCLC)}},
  author = {Damiano Fantini and Scott Coleman and Ekta Patel and Meghan Duncan and Martin Huber and Benjamin Nicholson and David Crowe and Scott McConnell and Patricia Bernardo and Myra W Popejoy and Carl Uli Bialucha},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0542},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0542},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 542 A first-in-human phase 1/2 study of XTX501, a bispecific PD-1/masked IL-2, in metastatic non-small cell lung cancer (NSCLC)
AU  - Damiano Fantini
AU  - Scott Coleman
AU  - Ekta Patel
AU  - Meghan Duncan
AU  - Martin Huber
AU  - Benjamin Nicholson
AU  - David Crowe
AU  - Scott McConnell
AU  - Patricia Bernardo
AU  - Myra W Popejoy
AU  - Carl Uli Bialucha
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0542
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0542
SN  - 2051-1426
ER  -